NCT04471987
Safety and Early Signs of Efficacy of IL12-L19L19.
레지스트리 요약
- 진행 상태
- 모집중 (RECRUITING)
- 질환/조건
- Advanced Solid Tumor, Metastatic Solid Tumor
- 시험 유형
- 중재 연구 (INTERVENTIONAL)
- 단계
- Phase 1
- 목적
- 치료
- 중재 유형
- 약물
- 개입·치료
- IL12-L19L19, IL12-L19L19
- Lead Sponsor
- Philogen S.p.A. (산업계)
캐시 시각: 2026-09-10 23:27:12
요약
The purpose of this study is to describe the safety, tolerability and early signs of efficacy of the antibody-cytokine fusion protein IL12-L19L19 in patients with advanced or metastatic solid carcinomas, after previous immune checkpoint blockade therapy.
The primary objective of the study is to evaluate the safety of IL12-L19L19 and to establish MTD in order to establish a recommended dose (RD).
The secondary objectives of the study are to assess early signs of efficacy, the determination of pharmacokinetic (PK) properties and the immunogenicity of IL12-L19L19.
The primary objective of the study is to evaluate the safety of IL12-L19L19 and to establish MTD in order to establish a recommended dose (RD).
The secondary objectives of the study are to assess early signs of efficacy, the determination of pharmacokinetic (PK) properties and the immunogenicity of IL12-L19L19.
카카오 로그인 후 의뢰